Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.2.1.23 (
beta-galactosidase
)
14,648
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We have recently described a new locus,
Hyal-1
, which determines hyaluronidase variants in mouse serum. On the basis of segregation in recombinant inbred and congenic strains,
Hyal-1
was tentatively assigned to chromosome 9 (Fiszer-Szafarz and De Maeyer, '89). In the present study we have performed a linkage analysis of
Hyal-1
using 156 backcross progeny of an interspecies cross of laboratory mice and Mus Spretus. Linkage was tested to two anchor loci on chromosome 9: d (dilute, a coat color locus) and Bgl-s (a locus controlling
beta-galactosidase
activity). The gene order (from centromere) with intervening percentage recombination is d-16.6 (+/- 2.9)-
Hyal-1
-10.9 (+/- 2.4)-Bgl-s, indicating close linkage to H-7 and Fv-2.
...
PMID:Linkage analysis of the murine Hyal-1 locus on chromosome 9. 202 49
In order to estimate the cumulative incidence rates of the mucopolysaccharidoses (MPS) in Germany, a retrospective epidemiological survey covering the period between 1980 and 1995 was implemented. Multiple ascertainment sources were used to identify affected patients. A prevalence of approximately 0.69 cases per 100,000 births was obtained for MPS I (Hurler phenotype). Within the study period, 4 patients with Hurler/Scheie phenotype and 7 cases with Scheie disease were detected. The cumulative incidence for MPS II (Hunter syndrome) was estimated as 0.64 cases per 100,000 births (1.3 cases per 100,000 male live births); that for MPS III (Sanfilippo syndrome types A, B and C) as 1.57 cases in 100,000 births; that for MPS IV A (Morquio syndrome) as 0.38 cases in 100,000; and that for MPS VI (Maroteaux-Lamy syndrome) as 0.23 cases per 100,000 births. Two cases of MPS IVB (
beta-galactosidase
deficiency) have been identified, but no patients with MPS VII or
MPS IX
. A relatively high number of patients with MPS IIIB, MPS IVA and MPS VI were of Turkish origin. The crude rate for all types of mucopolysaccharidoses is approximately 3.53 cases in 100,000 live births. The cumulative incidence pattern of MPS in Germany was compared with the corresponding rates among other industrial nations obtained from recent literature: the crude cumulative rates for all types of mucopolysaccharidoses (3.4-4.5 in 100,000 live births) were similar among all published populations; however, different frequencies of the various forms of MPS were observed.
...
PMID:Cumulative incidence rates of the mucopolysaccharidoses in Germany. 1643 94
It has been suggested that intracellular
Hyal-1
(hyaluronidase-1), which is considered a lysosomal enzyme, originates via endocytosis of the serum enzyme. To test this proposal we have investigated the uptake and intracellular distribution of rhHyal-1 (recombinant human
Hyal-1
) by mouse liver, making use of centrifugation methods. Experiments were performed on wild-type mice injected with 125I-labelled rhHyal-1 and on
Hyal-1
-/- mice injected with the unlabelled enzyme, which were killed at various times after injection. Activity of the unlabelled enzyme was determined by zymography. Intracellular distribution of
Hyal-1
was investigated by differential and isopycnic centrifugation. The results of the study indicated that rhHyal-1 is endocytosed by the liver, mainly by sinusoidal cells, and follows the intracellular pathway described for many endocytosed proteins that are eventually located in lysosomes. However,
Hyal-1
endocytosis has some particular features. First, endocytosed rhHyal-1 is quickly degraded. Secondly, its distribution, as analysed by differential centrifugation, differs from the distribution of
beta-galactosidase
, taken as the reference lysosomal enzyme. Further analysis by isopycnic centrifugation in a sucrose gradient shows endocytosed rhHyal-1 behaves like
beta-galactosidase
shortly after injection. However the
Hyal-1
distribution is markedly less affected than
beta-galactosidase
, following a prior injection of Triton WR-1339, which is a specific density perturbant of lysosomes. The behaviour in centrifugation of endogenous liver
Hyal-1
, identified by hyaluronan zymography, exhibits some similarity with the behaviour of the endocytosed enzyme, suggesting that it could originate from endocytosis of the serum enzyme. Overall, these results can be explained by supposing that active endocytosed
Hyal-1
is mainly present in early lysosomes. Although its degradation half-time is short,
Hyal-1
could exert its activity due to a constant supply of active molecules from the blood.
...
PMID:Endocytosis of hyaluronidase-1 by the liver. 2057 8